Abstract
Introduction Although the effectiveness of the HPV vaccine has been comprehensively described, adherence to dosing and limited budget is one of the causes of delay in HPV vaccination implementation in a country. A one-dose HPV vaccine could possibly solve those issues since several studies show promising results.
Areas covered This is a systematic review and meta-analysis focusing on the effectiveness of the one-dose HPV vaccine compared to two- and three doses of vaccination. We focused on clinical effectiveness, including prevention of HPV16, HPV18, and hrHPV infection, HSIL or ASC-H incidence, and CIN II/III incidence.
Expert opinion Our review showed that a one-dose HPV vaccine could potentially be as effective as two-or three doses since it offers immunogenic protection up to 8 years follow up and also prevention on infection and pre-cancers incidence. However, more studies and an extended duration of existing studies are required in order to provide robust evidence of this recommendation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NO
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
-
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Sources: These findings are the result of work supported by Universitas Muhammadiyah Purwokerto. Indonesia. The views expressed in this paper are those of the authors, and no official endorsement by Universitas Muhammadiyah Purwokerto is intended or should be inferred. NAN and MJP received no financial compensation for their contributions to this work.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
